Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29665117 | 1.00 | CYP2C19 (0.35) | CYP2C19HIF1ALMNAMAP2K1 | |
| SCHEMBL10305674 | 0.93 | CYP2C19 (0.39) | CYP2C19HIF1ALMNA | |
| SCHEMBL966684 | 0.84 | — | — | |
| SCHEMBL7056057 | 0.82 | CYP2C19 (0.36) | CYP2C19HIF1ALMNA | |
| SCHEMBL29665118 | 0.82 | CYP2C19 (0.36) | CYP2C19HIF1ALMNA | |
| SCHEMBL8720205 | 0.82 | CYP2C19 (0.36) | CYP2C19HIF1ALMNA | |
| SCHEMBL9000085 | 0.80 | CA2 (0.34) | — | |
| SCHEMBL28363240 | 0.79 | — | — | |
| SCHEMBL3259726 | 0.78 | LMNA (0.36) | CYP2C19HIF1ALMNA | |
| SCHEMBL8858993 | 0.78 | LMNA (0.47) | CYP2C19HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806500-A | Synthesis of ioversol polysubstituent | 大道隆达（北京）医药科技发展有限公司 | 2023-03-17 | — | — | CN | claimed |
| CN-115298162-A | Continuous crystallization method | 通用电气医疗集团股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| EP-2900632-A1 | PREPARATION OF AN INTERMEDIATE COMPOUND OF IOFORMINOL | GE HEALTHCARE AS (NO) | 2015-08-05 | — | — | EP | claimed |
| US-20120039815-A9 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-02-16 | — | — | US | claimed |
| EP-2385845-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2011-11-16 | — | — | EP | claimed |
| US-20110256068-A1 | CONTRAST MEDIA COMPOSITIONS | GE HEALTHCARE AS (NO) | 2011-10-20 | — | — | US | claimed |
| US-D647037-S1 | Tire tread | LO TSAI JEN | 2011-10-18 | — | — | US | claimed |
| US-20110052504-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-03-03 | — | — | US | claimed |
| EP-2277851-A1 | Acetylation using reduced volume of acetic acid anhydride for synthesizing non-ionic X-ray contrast agents | GE Healthcare AS (NO) | 2011-01-26 | — | — | EP | claimed |
| EP-2277859-A1 | Acetylation using reduced concentration of acetic acid anhydride for synthesizing non-ionic X-ray contrast agents | GE Healthcare AS (NO) | 2011-01-26 | — | — | EP | claimed |
| US-20110008263-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2011-01-13 | — | — | US | claimed |
| EP-2245003-A2 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106552-A2 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-09-03 | — | — | WO | claimed |
| EP-0886634-B1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT INC (US) | 2002-04-24 | — | — | EP | claimed |
| EP-0642492-B1 | 5,5'-/(1,3-PROPANEDIYL) BIS-/IMINO(2-OXO-2,1-ETHANEDIYL)ACETYLIMINO/BIS(2,4,6-TRIIODO-1,3-BENZENEDICARBOXYAMIDES), AND CONTRAST MEDIA CONTAINING THEM | BRACCO SPA (IT) | 1996-09-11 | — | — | EP | claimed |
| EP-0484328-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-N-ALKYLISOPHTHALAMIC ACID AND 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS. | MALLINCKRODT INC (US) | 1992-05-13 | — | — | EP | claimed |
| CN-117800986-A | Preparation method of ioversol impurity | 重庆圣华曦药业股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023150118-A1 | IODINATED COMPOUNDS AND HYDROGELS FORMED FROM SAME | BOSTON SCIENTIFIC SCIMED INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-1992018464-A1 | USE OF AZEOTROPIC DISTILLATION IN PROCESS TO DRY 5-AMINO-N,N'BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODOISOPHTHALAMIDE | MALLINCKRODT MEDICAL, INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0484328-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-N-ALKYLISOPHTHALAMIC ACID AND 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS. | MALLINCKRODT INC (US) | 1992-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039815-A9 | CONTRAST AGENTS | C5, TXN, CBR3 | CYP2C19 3568/4885HIF1A 337/4885LMNA 1863/4885 |
| US-20110052504-A1 | CONTRAST AGENTS | C5, TXN, CBR3 | CYP2C19 3568/4885HIF1A 337/4885LMNA 1863/4885 |
| US-20110008263-A1 | CONTRAST AGENTS | C5, C1R, C3AR1 | CYP2C19 2085/4885HIF1A 1353/4885LMNA 1002/4885 |
| US-20110256068-A1 | CONTRAST MEDIA COMPOSITIONS | FPR1, FPR3, TPO | CYP2C19 4295/4885HIF1A 1948/4885LMNA 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.